J65 Peptide Vaccine
DRACPC ID DRACPC0103
Active Ingredients J65 Peptide Vaccine
Description A cancer vaccine comprised of human leukocyte antigen (HLA)-A2-restricted folate binding protein (FBP) epitope J65 (9 amino acids; EIWTFSTKV), with potential immunostimulatory and antineoplastic activities. Upon intradermal injection, FBP J65 peptide vaccine may induce a specific cytotoxic T-lymphocyte (CTL) response against J65 FBP-expressing tumor cell types. FBP is a membrane-bound, tumor-associated antigen overexpressed in various tumor types, including breast, ovarian and endometrial cancers. J65 is a strongly immunogenic peptide.
Synonyms FBP J65 Peptide Vaccine; Folate Binding Protein J65 Peptide Vaccine; J65 Peptide Vaccine
Type Biotech
Disease Breast Cancer, Ovarian Cancer
Classification
Peptide and derivative Vaccine
Structure Information
Molecular Formula Not available
Molecular Weight Not available
Active Sequence EIWTFSTKV
Sequence Length 9
Modification Not available
Structure
IUPAC Name Not available
InChI Not available
InChI_Key Not available
SMILES Not available
External Codes
PubChem CID Not available
DrugBank Accession Number Not available
NCI Thesaurus Code C113660
UNII Not available
CAS Not available
Drug approval
Drug indication
Investigated for use/treatment in Breast Cancer, Ovarian Cancer.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT02019524 | Phase Ib Trial of Two Folate Binding Protein (FBP) Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients | Breast Cancer; Ovarian Cancer | Phase 1 | Treatment |
| NCT01580696 | Phase I/IIa Trial of Folate Binding Protein (FBP) Peptide (E39) Vaccine in Ovarian and Endometrial Cancer Patients | Ovarian Cancer; Endometrial Cancer; Fallopian Cancer; Peritoneal Cancer | Phase 1/2 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
